Biotech Sector Sees Significant Swings on Clinical Trial Data

Candel Therapeutics, Inc. (Nasdaq: CADL) announced clinical and biomarker data from its phase 3 PrTK03 and phase 2 PrTK05 trials evaluating aglatimagene besadenovec in patients with intermediate-risk localized prostate cancer, according to a company press release.

In the PrTK03 phase 3 trial, 635 patients with intermediate-risk disease treated with aglatimagene plus external beam radiation therapy (EBRT) showed a 41% reduction in the risk of prostate cancer recurrence or prostate cancer-specifi

Investing.com -- Rafael Holdings Inc Class B (NYSE: RFL) shares fell 25% in premarket trading Wednesday after the company's Phase 3 trial of Trappsol Cyclo for Niemann-Pick Disease Type C failed to meet its primary endpoint.

The TransportNPC study, which enrolled 94 patients, showed Trappsol Cyclo did not achieve statistical significance on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale at Week 96. The drug demonstrated a directionally favorable treatment effect vers

Investing.com -- Sagimet Biosciences Inc Series A (NASDAQ: SGMT) shares rose over 12% in premarket trading Wednesday following positive 52-week results from its license partner Ascletis' Phase 3 open-label extension trial of denifanstat for moderate to severe acne.

The trial showed denifanstat achieved a 57% treatment success rate, with a 72% reduction in total lesions and 77% reduction in inflammatory lesions after 52 weeks of treatment. The drug was generally well-tolerated, with no adverse e

Theriva Biologics (NYSE American: TOVX) announced that results from its VIRAGE Phase 2b clinical trial of VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic cancer patients were published in Nature Medicine, according to a company statement.

The trial enrolled 112 patients across 14 sites in the U.S. and Spain. Patients in the VCN-01 treatment arm received intravenous VCN-01 seven days prior to the first and fourth cycles of standard-of-care gemcitabine/nab-paclitaxel chemotherapy. The

Merck (MRK) announced results from a Phase 2b trial of tulisokibart, an investigational monoclonal antibody, in patients with moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The data were presented at the European Academy of Dermatology and Venereology 2026 Congress.

The trial, designated MK-7240-012, met its primary endpoint of HiSCR50 — a 50% reduction in abscesses and inflammatory nodules — at week 16. In the high-dose group (480 mg every two weeks), 72

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY) announced today that its drug Ebglyss met primary and secondary endpoints in a Phase 3b clinical trial for patients with moderate-to-severe hand and foot atopic dermatitis, according to a press release statement.

The ADtouch study evaluated 221 adults and adolescents who received either Ebglyss or placebo every two weeks for 16 weeks. At Week 16, 53% of patients treated with Ebglyss achieved clear or almost clear skin on hands and feet, compared t

CAMBRIDGE, Mass. - Sarepta Therapeutics Inc. (NASDAQ:SRPT) presented data on Wednesday showing functional outcomes for its gene therapy Elevidys in ambulatory Duchenne muscular dystrophy patients aged 8 to 12 years at the World Muscle Society Congress.

The analysis compared 25 treated patients from the EMBARK and ENDEAVOR studies with 99 patients from external control datasets. At two years, treated patients showed a 3.32-point difference in North Star Ambulatory Assessment scores compared to t